Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 3,128 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $15,890.24. Following the completion of the sale, the chief technology officer now directly owns 1,762,776 shares of the company's stock, valued at approximately $8,954,902.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
David Badawi also recently made the following trade(s):
- On Wednesday, January 17th, David Badawi sold 3,414 shares of Sight Sciences stock. The stock was sold at an average price of $5.16, for a total value of $17,616.24.
Sight Sciences Stock Performance
Shares of SGHT opened at $5.58 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.29 and a quick ratio of 12.65. Sight Sciences, Inc. has a one year low of $1.04 and a one year high of $11.20. The firm has a market capitalization of $276.49 million, a P/E ratio of -4.89 and a beta of 2.83. The business has a fifty day moving average of $4.59 and a 200 day moving average of $3.89.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million for the quarter, compared to the consensus estimate of $18.70 million. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. During the same period in the previous year, the business earned ($0.35) earnings per share. As a group, sell-side analysts anticipate that Sight Sciences, Inc. will post -1.04 EPS for the current year.
Hedge Funds Weigh In On Sight Sciences
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several institutional investors and hedge funds have recently bought and sold shares of SGHT. UBS Group AG lifted its position in Sight Sciences by 20,282.6% during the fourth quarter. UBS Group AG now owns 2,895,958 shares of the company's stock valued at $14,943,000 after purchasing an additional 2,881,750 shares in the last quarter. Apollo Management Holdings L.P. purchased a new position in Sight Sciences during the first quarter valued at $5,869,000. JPMorgan Chase & Co. lifted its position in Sight Sciences by 103.3% during the second quarter. JPMorgan Chase & Co. now owns 1,117,981 shares of the company's stock valued at $9,257,000 after purchasing an additional 568,135 shares in the last quarter. First Republic Investment Management Inc. purchased a new position in Sight Sciences during the second quarter valued at $4,961,000. Finally, Vanguard Group Inc. lifted its position in Sight Sciences by 92.9% during the first quarter. Vanguard Group Inc. now owns 1,082,725 shares of the company's stock valued at $12,517,000 after purchasing an additional 521,412 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
